Dissection of
PIK3CA
cervical adenocarcinoma
mutation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jun 2021
28 Jun 2021
Historique:
received:
06
04
2021
revised:
07
06
2021
accepted:
15
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in
Identifiants
pubmed: 34203201
pii: cancers13133218
doi: 10.3390/cancers13133218
pmc: PMC8269188
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hong Kong Research Grant Council
ID : 14101315
Références
Gynecol Oncol. 2013 Mar;128(3):409-14
pubmed: 23266353
Cancer. 2013 Nov 1;119(21):3776-83
pubmed: 24037752
Cell Cycle. 2009 May 1;8(9):1352-8
pubmed: 19305151
Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17
pubmed: 28599900
J Natl Cancer Inst Monogr. 2003;(31):35-40
pubmed: 12807943
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Semin Cancer Biol. 2019 Dec;59:36-49
pubmed: 30742905
Sci Rep. 2015 Sep 11;5:14035
pubmed: 26358014
Oncotarget. 2015 Mar 10;6(7):4968-75
pubmed: 25669975
Exp Ther Med. 2019 Sep;18(3):2278-2284
pubmed: 31410178
EBioMedicine. 2019 May;43:253-260
pubmed: 30952619
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820921248
pubmed: 32329414
Int J Cancer. 2015 Aug 15;137(4):776-83
pubmed: 25626421
Medicine (Baltimore). 2018 Aug;97(31):e11392
pubmed: 30075505
Ann Oncol. 2019 Jun 1;30(6):945-952
pubmed: 30860573
Cancer. 2020 Jan 15;126(2):373-380
pubmed: 31769875
Mod Pathol. 2017 Nov;30(11):1633-1641
pubmed: 28731050